A cohort study of 214 human immunodeficiency virus (HIV) -infected patients was performed to assess the usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death. Multivariate analysis revealed that only positive baseline CMV antigenemia assays (relative risk [RR], 7.2; 95% confidence interval [CI], 3.7 -14.2; P Å .0001) and CD4 cell counts (RR, 0.98; 95% CI, 0.97 -0.99; P Å .009) were associated with CMV disease. A positive baseline CMV antigenemia assay was also associated with death by multivariate analysis (RR, 2.2; 95% CI, 1.5 -3.4; P Å .0003). Increasing levels of CMV antigenemia during follow-up were associated with increased risks of CMV disease and death. A positive CMV antigenemia assay that showed ú10 cells per 2 1 10 5 polymorphonuclear leukocytes during follow-up was 91% sensitive and 84% specific for predicting a diagnosis of CMV disease; the negative predictive value for this positive test was high (97%). Therefore, the CMV antigenemia assay appears to be a simple, rapid, and inexpensive test for predicting the occurrence of CMV disease and death in patients with advanced HIV infection.
Cytomegalovirus (CMV) remains the most common and senosis of CMV disease in HIV-infected patients [7 -11] . The CMV antigenemia assay is a simple and inexpensive quantitarious viral opportunistic pathogen in patients with advanced HIV infection. Although CMV infection mainly induces sighttive technique to assess CMV viremia, the results of which are usually available within 5 hours. However, little information threatening retinitis, it can also involve the gastrointestinal tract as well as the CNS and peripheral nervous system [1] . Despite is available on the association of CMV antigenemia levels and survival in large cohorts of patients with AIDS. Therefore, we significant advances in the treatment of CMV disease in patients with AIDS, disease relapses are usual and are associated performed a cohort study to assess the value of the CMV antigenemia assay for predicting the occurrence of CMV diswith decreased survival [2, 3] . CMV disease in patients with HIV infection is often associated with viremia. A number of ease and death in patients with advanced HIV infection. The results of this study should be useful for selecting patients with assays that detect CMV in blood and that quantitate viral load have been developed in an effort to identify patients at highest advanced HIV infection who will require primary prophylaxis or preemptive therapy for CMV disease [12] . risk for CMV disease for whom prevention strategies could be tested. For these patients, the diagnostic value of CMV viremia detected by culture or PCR analysis for CMV disease is well Patients and Methods known [4 -6] .
The CMV pp65 antigenemia assay has also been recently Patients. During the study period (from 1 January 1994 to proposed as another reliable and sensitive method for the diag-31 December 1996), the CMV antigenemia assay was performed for 370 HIV-infected patients followed up in our of õ200/mm 3 , the presence of antibodies to CMV, no previous . To assess the predictive value CMV antigenemia assay. The CMV antigenemia assay was of serial CMV antigenemia tests, Cox regression with a timecarried out with a commercially available kit (CINAkit; Argene dependent covariate and likelihood ratio statistics for testing Biosoft, Varilhes, France) by using indirect immunofluoresnull hypotheses was used. Owing to the finite number of CMV cence as described elsewhere [14] according to the manufacturantigenemia measures, an interpolation convention was reer's instructions. Polymorphonuclear leukocytes (PMNLs) quired to assign values for times intermediate between observawere separated from 5 mL of heparinized blood by dextran tions. It consisted of defining a time window for all available sedimentation. After lysis of contaminated erythrocytes, a measurements and extending the CMV antigenemia values to PMNL suspension containing 2 1 10 5 cells was cytocentrithose during times intermediate between observations. SAS fuged, formaldehyde fixed, and processed in an indirect immusoftware (SAS Institute, Cary, NC) was used. nofluorescence stain with a combination of monoclonal antibodies (AC3 / AYM-1) to the CMV protein pp65 as the primary antibody and a fluorescein-conjugated F(ab)2 goat Results antibody to mouse IgG and IgM as the secondary antibody. CMV pp65 -positive cells were counted under a fluorescence Study population. Of the 370 patients for whom CMV antigenemia assays were performed during the study period, 156 microscope by using a 1400 magnification. Positively stained leukocytes were easy to detect on the basis of an intense green (42%) were excluded from this cohort study. Reasons for exclusion included the following: lack of antibodies to CMV (22 nuclear fluorescence. The results were expressed as the number of positive cells per 2 1 10 5 leukocytes examined. patients), follow-up of õ2 months without occurrence of CMV disease or death (58), previous CMV disease or previous antiAssays for antibodies to CMV. The detection of IgG antibodies to CMV was performed with an EIA (Enzygnost Anti-CMV treatment (41), and baseline CD4 cell count of ú200/mm 3 (35). Therefore, statistical analysis was performed CMV/IgG; Behring, Marburg, Germany) according to the manufacturer's instructions. on data for only 214 patients (58% had the highest specificity (99%) and positive predictive value (90%); sensitivity of these assays, however, was only 38%. Using repeated CMV antigenemia measurements, only 45 of the median age of the patients was 37.5 years (range, 23 -77 the 125 patients with at least one positive CMV antigenemia years). Regarding HIV risk factors, 136 patients (64%) were test during follow-up were later affected by CMV (positive homosexuals, 47 (22%) were injecting drug users, and 21 predictive value, 36%) over the observation period of 10.5 (10%) were heterosexuals; risk factors were unknown for 10 months. However, only two of the 89 patients with consistently (4%). These patients had advanced HIV infection; the median negative tests developed CMV disease (negative predictive CD4 count at baseline was 36/mm 3 . Most patients (74%) alvalue, 97%). Using the cutoff of 10 cells, 70 patients had at ready had had AIDS-defining diseases (a CDC clinical classifileast one positive test, and 43 developed CMV disease. The cation of HIV infection of C). Sixty-nine patients (32%) had positive predictive value increased to 61%, while the negative positive CMV antigenemia assays at the first determination, predictive value remained at 97%. and the median time between two determinations was 30 days;
Univariate analysis of different baseline risk factors for the this median time was longer for patients with negative CMV occurrence of CMV disease identified only three risk factors: antigenemia assays at baseline than for patients with positive CMV antigenemia, CD4 cell counts, and a CDC clinical classi-CMV antigenemia assays at baseline (36 days vs. 23.5 days, fication of HIV infection of C (data not shown). Multivariate respectively; P Å .001, Wilcoxon rank-sum test). The mean analysis, however, revealed that only baseline CMV antigennumber of tests per patient was 3.6 (range, 1 -18). emia assays (RR, 7.2; 95% CI, 3.7 -14.2; P Å .0001) and CD4 Incidence and risk factors for CMV disease. The mean cell counts (RR, 0.98; 95% CI, 0.97 -0.99; P Å .009) were duration of follow-up { SD for the cohort was 10.5 { 6 months. During the study period, 47 patients (22%) developed significantly associated with CMV disease. In patients with infection of C (RR, 2.4; 95% CI, 1.4 -4.3; P Å .002) were significantly associated with death, whereas CD4 cell count in patients who developed CMV disease. The median survival time was 14.6 months. The Kaplan-Meier estimates of the was not. Finally, the occurrence of CMV disease increased the risk of death by 4.0 (95% CI, 2.6 -6.0); this relative risk of overall survival in the study population according to the results of baseline CMV antigenemia assays are shown in figure 2 .
death after CMV disease was estimated at 3.1 (95% CI, 1.8 -5.2) following an adjustment according to CMV antigenemia The 12-month mortality rate was 39%. This rate significantly increased according to results of baseline CMV antigenemia assay and a CDC clinical classification of HIV infection of C at baseline. assays, ranging from 30% among patients with negative baseline tests to 60% among those with positive baseline tests (P Å .0001, logrank test). Discussion Median survival was 20 months for patients with positive baseline CMV antigenemia assays and decreased to 10. 4 The goal of this cohort study was to assess the usefulness of the CMV antigenemia assay for predicting the occurrence months for patients with positive baseline CMV antigenemia assays. Median survival was only 7.2 months for patients with of CMV disease and death in patients with advanced HIV infection. The CMV antigenemia assay is a direct method for baseline CMV antigenemia assays revealing ú50 cells. The relative risks of death according to results of baseline CMV identifying CMV in peripheral blood PMNLs, and its results can be quantified. Several studies have shown that the sensitivantigenemia assays are shown in table 2. Univariate analysis of different baseline risk factors for survival (including occurity of the CMV antigenemia assay is superior to that of standard cell cultures or shell vial cultures for the diagnosis of CMV rence of CMV disease) identified only three risk factors: CMV [8] in their study of 49 patients. It is interesting that our study provides additional information regarding the value of CMV antigenemia as a predictor of survival. Indeed, survival in our cohort significantly decreased with increasing baseline CMV antigenemia levels ( figure 2 ). In addition, multivariate analysis revealed that baseline CMV antigenemia and a CDC clinical classification of HIV infection of C were the only risk factors significantly associated with survival. Despite the retrospective nature of our cohort study, its size (214 patients), the way that data were collected (demographics and onset of CMV disease and death were recorded without knowledge of the results of CMV antigenemia assays), and the strong associations between CMV antigenemia values and the occurrence of CMV disease and deaths make it unlikely that our results are significantly biased. Similar results were recently reported by Spector et al. [19] (CMV) antigenemia assay for predicting CMV disease and death who used PCR analysis for quantitation of CMV DNA in in patients with AIDS; the estimates were based on baseline CMV plasma, and recent studies [4, 19, 20] seem to indicate that antigenemia levels: Å negative; ---Å £10 cells; Å PCR analysis might be the most sensitive and specific assay £50 cells; Å ú50 cells.
for the early diagnosis of CMV infection. However, the CMV PCR assay is not yet standardized, and its cost is higher (approximately fivefold) than that of the CMV antigenemia assay. disease in transplant recipients, but fewer data are available for HIV-infected patients [9, 17, 18] . The CMV antigenemia
On the contrary, the CMV antigenemia assay is commercially available and does not need sophisticated laboratory equipment. assay has other advantages over culture techniques. The test is relatively simple to perform and reveals the leukocytic viral It is very appropriate for daily clinical practice. The identification of a virological assay that is able to predict, reliably and load with a negligible delay (5 hours) [14] . However, this test requires technical skills for an accurate reading of the slides.
timely, the occurrence of CMV disease is particularly important to identify patients at higher risk who should be eligible for Our results clearly show that the CMV antigenemia assay can identify HIV-infected patients at high risk of CMV disease; our prophylaxis studies. CMV antigenemia and CMV PCR assays currently appear to be the most valuable tests to assess CMV data also demonstrate that the quantitation of CMV antigen in blood provides useful additional information. The incidence of viremia in patients with AIDS. In a recent prospective study, Dodt et al. [4] evaluated both CMV disease significantly increases as the level of baseline CMV antigenemia increases (figure 1). A positive CMV antigenemia tests for patients with HIV infection. Both the plasma CMV PCR assay and the CMV antigenemia assay were sensitive assay revealing ú10 cells at baseline was 94% specific and 62% sensitive for predicting a diagnosis of CMV disease; the median methods to predict the development of CMV disease up to several months before clinical disease and performed better time between a positive CMV antigenemia assay and the onset of CMV disease was 181 days (table 3) . Repeated measurements than CMV cultures. The sensitivity and specificity of the CMV PCR assay appeared however to be slightly superior to those of CMV antigenemia during follow-up (using the same threshold value as 10 positive cells) revealed that the sensitivity increased of the CMV antigenemia assay with regard to the detection of CMV DNA in plasma. In their study, CMV antigenemia was to 91% and the specificity was 84% (table 4) . Multivariate analysis of different baseline risk factors for the occurrence of CMV disdetected a median of 34 days before the onset of CMV disease. This finding is in sharp contrast with our results: the median ease showed that the CMV antigenemia assay was the strongest predictor (RR, 7.2; 95% CI, 3.7-14.2). The only other baseline time between the detection of CMV antigenemia and the onset of CMV disease was as long as 255 days (similar to the duration risk factor associated with CMV disease in this model was the CD4 cell count: as expected, the relative risk is lower when the of 301 days that was reported by Francisci et al. [8] ). Reasons for this discrepancy might be related to a different study popu-CD4 cell count increases. Previous data have already indicated that the CD4 lymphocyte count is a strong predictor of risk of lation or rather to a different CMV antigenemia test. We and Francisci et al. [8] used the same kit for monoclonal antibodies CMV disease in patients with AIDS [2, 5] .
The data from this study demonstrate that for HIV-infected to the CMV pp65 proteins for the detection of CMV antigenemia by immunofluorescence, whereas Dodt et al. [4] used an patients with a very low CD4 cell count (median, 36/mm 3 ), although CD4 cell counts remained associated with CMV disalkaline phosphatase staining procedure. In another prospective comparative study of different CMV ease, the presence and the level of CMV antigenemia better identifies patients at highest risk for development of CMV blood markers to assess the risk of CMV disease in patients / 9c64$$ap06 03-15-99 09:12:24 cida UC: CID
